HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $56,054,639 | +12.7% | 1,467,234 | +6.4% | 0.02% | +12.5% |
| Q2 2023 | $49,719,882 | -7.1% | 1,378,639 | -1.6% | 0.02% | -11.1% |
| Q1 2023 | $53,499,801 | +62494.8% | 1,401,012 | -6.7% | 0.02% | -28.0% |
| Q4 2022 | $85,470 | -99.9% | 1,502,107 | -2.0% | 0.02% | +8.7% |
| Q3 2022 | $60,635,000 | +2.1% | 1,533,500 | +13.7% | 0.02% | +9.5% |
| Q2 2022 | $59,361,000 | +26.7% | 1,349,014 | +14.8% | 0.02% | +50.0% |
| Q1 2022 | $46,862,000 | +2.4% | 1,175,014 | +3.2% | 0.01% | 0.0% |
| Q4 2021 | $45,774,000 | -4.9% | 1,138,363 | -3.8% | 0.01% | -12.5% |
| Q3 2021 | $48,149,000 | +45.9% | 1,183,621 | +62.9% | 0.02% | +60.0% |
| Q2 2021 | $32,997,000 | +142.5% | 726,644 | +122.7% | 0.01% | +150.0% |
| Q1 2021 | $13,605,000 | +104.3% | 326,266 | +109.2% | 0.00% | +100.0% |
| Q4 2020 | $6,660,000 | +172.7% | 155,947 | +67.8% | 0.00% | +100.0% |
| Q3 2020 | $2,442,000 | -10.9% | 92,931 | -9.2% | 0.00% | 0.0% |
| Q2 2020 | $2,740,000 | +48.9% | 102,313 | +0.1% | 0.00% | 0.0% |
| Q1 2020 | $1,840,000 | +4.1% | 102,241 | +2.6% | 0.00% | 0.0% |
| Q4 2019 | $1,767,000 | +4.7% | 99,636 | -8.4% | 0.00% | 0.0% |
| Q3 2019 | $1,687,000 | -53.1% | 108,819 | -48.0% | 0.00% | 0.0% |
| Q2 2019 | $3,597,000 | -78.2% | 209,392 | -79.6% | 0.00% | -85.7% |
| Q1 2019 | $16,501,000 | +2.8% | 1,024,932 | -6.6% | 0.01% | 0.0% |
| Q4 2018 | $16,050,000 | +10.1% | 1,097,080 | +36.8% | 0.01% | +16.7% |
| Q3 2018 | $14,575,000 | +34.2% | 802,171 | +24.6% | 0.01% | +50.0% |
| Q2 2018 | $10,862,000 | +51.6% | 643,822 | +76.0% | 0.00% | +33.3% |
| Q1 2018 | $7,167,000 | +3172.6% | 365,869 | +2147.1% | 0.00% | – |
| Q3 2015 | $219,000 | +2090.0% | 16,282 | +1528.2% | 0.00% | – |
| Q4 2014 | $10,000 | +11.1% | 1,000 | 0.0% | 0.00% | – |
| Q3 2014 | $9,000 | -25.0% | 1,000 | -16.7% | 0.00% | – |
| Q2 2014 | $12,000 | -20.0% | 1,200 | 0.0% | 0.00% | – |
| Q1 2014 | $15,000 | -16.7% | 1,200 | 0.0% | 0.00% | – |
| Q4 2013 | $18,000 | +38.5% | 1,200 | 0.0% | 0.00% | – |
| Q3 2013 | $13,000 | +30.0% | 1,200 | 0.0% | 0.00% | – |
| Q2 2013 | $10,000 | – | 1,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |